Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of eliminating Pneumocystis jirovecii colonization on inflammation in COPD
2012-001585-14Phase 4Active
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of atovaquone in chronic obstructive pulmonary disease (COPD) and pneumocystis pneumonia (PCP), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Primary endpoint: IL-6 reduction after treatment. Started Oct 2012; status: active.
02
Drugs
atovaquone
03
Conditions
chronic obstructive pulmonary disease (COPD)pneumocystis pneumonia (PCP)
Beyond the preview
Go deeper on 2012-001585-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001585-14.